A Randomized Study of Olaparib or Placebo in Patients With Surgically Removed Pancreatic Cancer Who Have a BRCA1, BRCA2 or PALB2 Mutation, The APOLLO Trial
Conditions: Pancreatic Acinar Cell Carcinoma; Pancreatic Adenosquamous Carcinoma; Pancreatic Carcinoma; Pancreatic Squamous Cell Carcinoma; Resectable Pancreatic Acinar Cell Carcinoma; Resectable Pancreatic Adenocarcinoma; Resectable Pancreatic Adenosquamous Carcinoma; Resectable Pancreatic Carcinoma; Stage 0 Pancreatic Cancer AJCC v8; Stage I Pancreatic Cancer AJCC v8; Stage IA Pancreatic Cancer AJCC v8; Stage IB Pancreatic Cancer AJCC v8; Stage II Pancreatic Cancer AJCC v8; Stage IIA Pancreatic Cancer AJCC v8; Stage IIB Pancreatic Cancer AJCC v8
Interventions: Drug: Olaparib; Drug: Placebo Administration
Sponsor: National Cancer Institute (NCI)
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.